Immunocore Holdings (IMCR) Operating Leases (2019 - 2026)

Immunocore Holdings has disclosed Operating Leases across 8 years of filings, most recently posting $40.0 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $40.0 million, down 5.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.0 million (down 5.74% YoY), and the FY2025 annual result was $41.6 million, up 3.47% from the prior year.
• Operating Leases came in at $40.0 million for Q1 2026 at Immunocore Holdings, down from $41.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $42.6 million in Q2 2025 to a low of $33.1 million in Q4 2022.
• The 5-year median for Operating Leases is $40.2 million (2024), against an average of $38.9 million.
• Across the five-year window, Operating Leases grew 22.19% in 2025 and slipped 5.74% in 2026, its largest moves.
• Immunocore Holdings' Operating Leases stood at $33.1 million in 2022, then rose by 7.48% to $35.6 million in 2023, then advanced by 12.78% to $40.2 million in 2024, then climbed by 3.47% to $41.6 million in 2025, then fell by 3.68% to $40.0 million in 2026.
• The last three Operating Leases figures came in at $40.0 million (Q1 2026), $41.6 million (Q4 2025), and $41.4 million (Q3 2025), per Business Quant data.